Zelgen signed license agreement for new three-pronged antibody drug ZGGS001

On August 17, Zelgen announced that it had signed an exclusive license agreement with its holding subsidiary Gensun Biopharma, Inc. on August 14, 2020.

On August 17, Zelgen announced that it had signed an exclusive license agreement with its holding subsidiary Gensun Biopharma, Inc. on August 14, 2020.

The two parties cooperated in the development of the new three-pronged antibody drug ZGGS001 and allowed the former to obtain the exclusive patent authorization in the Greater China region (including mainland China, Hong Kong, Macau and Taiwan).

ZGGS001 is a novel three-pronged antibody molecule, which mainly inhibits tumor immunity and multiple tumor angiogenesis pathways, and regulates the tumor microenvironment.

In addition, ZGGS001 has good expression, stability and druggability. Currently, this product is in the pre-clinical development stage.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/08/18/zelgen-signed-license-agreement-for-new-three-pronged-antibody-drug-zggs001/.

Leave a Reply

Please Login to Comment